Cargando…

Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients

This study examines whether women with breast cancer, who are adherent and non-adherent to tamoxifen, differ in their perceptions of information received during treatment. This cross-sectional study included women receiving tamoxifen as adjuvant treatment for breast cancer recruited from a teaching...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz, Aline, Rodrigues, Aline, Ferracini, Amanda, Stahlschmidt, Rebeca, Silva, Nice, Mazzola, Priscila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798421/
https://www.ncbi.nlm.nih.gov/pubmed/29416436
http://dx.doi.org/10.5114/wo.2017.72397
_version_ 1783297850857226240
author Cruz, Aline
Rodrigues, Aline
Ferracini, Amanda
Stahlschmidt, Rebeca
Silva, Nice
Mazzola, Priscila
author_facet Cruz, Aline
Rodrigues, Aline
Ferracini, Amanda
Stahlschmidt, Rebeca
Silva, Nice
Mazzola, Priscila
author_sort Cruz, Aline
collection PubMed
description This study examines whether women with breast cancer, who are adherent and non-adherent to tamoxifen, differ in their perceptions of information received during treatment. This cross-sectional study included women receiving tamoxifen as adjuvant treatment for breast cancer recruited from a teaching hospital specialised in women’s health in the state of São Paulo (Brazil). Women were interviewed and their records were reviewed for socio demographic data and clinical characteristics. We assessed tamoxifen adherence using the Morisky-Green Test, and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire – Information module (EORTC QLQ-INFO25) was used to evaluate the information received by the women. The sample contained 31 women (mean age = 55.4; SD = 11.6 years). According to the Morisky-Green Test, 74.2% of the women had suboptimal tamoxifen adherence. The global score for women’s perceptions of information they received about the treatment and disease was 57.0 ±19.1 on a scale of 0 to 100, and no significant differences in scores were observed between adherents and non-adherents. A high prevalence of suboptimal tamoxifen adherence was observed. We found no significant differences between women with breast cancer who were adherent and non-adherent to tamoxifen.
format Online
Article
Text
id pubmed-5798421
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-57984212018-02-07 Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients Cruz, Aline Rodrigues, Aline Ferracini, Amanda Stahlschmidt, Rebeca Silva, Nice Mazzola, Priscila Contemp Oncol (Pozn) Original Paper This study examines whether women with breast cancer, who are adherent and non-adherent to tamoxifen, differ in their perceptions of information received during treatment. This cross-sectional study included women receiving tamoxifen as adjuvant treatment for breast cancer recruited from a teaching hospital specialised in women’s health in the state of São Paulo (Brazil). Women were interviewed and their records were reviewed for socio demographic data and clinical characteristics. We assessed tamoxifen adherence using the Morisky-Green Test, and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire – Information module (EORTC QLQ-INFO25) was used to evaluate the information received by the women. The sample contained 31 women (mean age = 55.4; SD = 11.6 years). According to the Morisky-Green Test, 74.2% of the women had suboptimal tamoxifen adherence. The global score for women’s perceptions of information they received about the treatment and disease was 57.0 ±19.1 on a scale of 0 to 100, and no significant differences in scores were observed between adherents and non-adherents. A high prevalence of suboptimal tamoxifen adherence was observed. We found no significant differences between women with breast cancer who were adherent and non-adherent to tamoxifen. Termedia Publishing House 2017-12-30 2017 /pmc/articles/PMC5798421/ /pubmed/29416436 http://dx.doi.org/10.5114/wo.2017.72397 Text en Copyright: © 2017 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Cruz, Aline
Rodrigues, Aline
Ferracini, Amanda
Stahlschmidt, Rebeca
Silva, Nice
Mazzola, Priscila
Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients
title Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients
title_full Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients
title_fullStr Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients
title_full_unstemmed Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients
title_short Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients
title_sort analysis of information received during treatment and adherence to tamoxifen in breast cancer patients
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798421/
https://www.ncbi.nlm.nih.gov/pubmed/29416436
http://dx.doi.org/10.5114/wo.2017.72397
work_keys_str_mv AT cruzaline analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients
AT rodriguesaline analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients
AT ferraciniamanda analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients
AT stahlschmidtrebeca analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients
AT silvanice analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients
AT mazzolapriscila analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients